Literature DB >> 7538128

Topography of ligand-induced binding sites, including a novel cation-sensitive epitope (AP5) at the amino terminus, of the human integrin beta 3 subunit.

S Honda1, Y Tomiyama, A J Pelletier, D Annis, Y Honda, R Orchekowski, Z Ruggeri, T J Kunicki.   

Abstract

Changes in ligand binding ability of the integrin alpha IIb beta 3 can be monitored by the concomitant expression of ligand-inducible binding sites (LIBS). A new LIBS, the hexapeptide sequence GPNICT (residues 1-6) at the amino terminus of beta 3 recognized by the murine monoclonal antibody (mAb) AP5, is sensitive both to the binding of ligand and to micromolar differences in divalent cation levels. Calcium or magnesium can completely inhibit the binding of AP5 to alpha IIb beta 3 on platelets, with ID50 values of 80 and 1500 microM, respectively. The inhibitory effect of calcium plus magnesium is cumulative. In the presence of 1 mM calcium plus 1 mM magnesium, the peptide RGDW overcomes this inhibition and induces maximal binding of AP5. Maximal AP5 binding is also induced by a molar excess of EDTA. The unique location of the AP5 LIBS was determined by comparing the binding of LIBS-specific mAb to recombinant human-Xenopus beta 3 chimeras produced in a baculovirus expression system. AP5 defines one region at the amino terminus beta 3 1-6. A second region, defined by mAb D3GP3, is probably located within beta 3 422-490, confirming the finding of Kouns et al. (Kouns, W. C., Newman, P.J., Puckett, K. J., Miller, A. A., Wall, C. D., Fox, C. F., Seyer, J. M., and Jennings, L. K. (1991) Blood 78, 3215-3223). The third region, encompassing at most residues 490-690, and perhaps more precisely located within 602-690 (Du X., Gu, M., Weise, J. W., Nagaswami, C., Bennett, J. S., Bowditch, R., and Ginsberg, M. H. (1993) J. Biol. Chem. 268, 23087-23092), is recognized by the four mAb, anti-LIBS2, anti-LIBS3, anti-LIBS6, and P41. Since its exposure is uniquely regulated by both divalent cations and ligand, the amino terminus of beta 3 may be involved in control of ligand binding by divalent cation mobilization.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7538128     DOI: 10.1074/jbc.270.20.11947

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  53 in total

1.  Stabilizing the open conformation of the integrin headpiece with a glycan wedge increases affinity for ligand.

Authors:  Bing-Hao Luo; Timothy A Springer; Junichi Takagi
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-25       Impact factor: 11.205

2.  Modulation of integrin activation by an entropic spring in the {beta}-knee.

Authors:  Benoit J Smagghe; Po-Ssu Huang; Yih-En Andrew Ban; David Baker; Timothy A Springer
Journal:  J Biol Chem       Date:  2010-07-28       Impact factor: 5.157

3.  Effects of limiting extension at the alphaIIb genu on ligand binding to integrin alphaIIbbeta3.

Authors:  Robert Blue; Jihong Li; Jonathan Steinberger; Marta Murcia; Marta Filizola; Barry S Coller
Journal:  J Biol Chem       Date:  2010-04-02       Impact factor: 5.157

Review 4.  Integrin structures and conformational signaling.

Authors:  Bing-Hao Luo; Timothy A Springer
Journal:  Curr Opin Cell Biol       Date:  2006-08-14       Impact factor: 8.382

5.  Mapping early conformational changes in alphaIIb and beta3 during biogenesis reveals a potential mechanism for alphaIIbbeta3 adopting its bent conformation.

Authors:  W Beau Mitchell; Jihong Li; Marta Murcia; Nathalie Valentin; Peter J Newman; Barry S Coller
Journal:  Blood       Date:  2007-01-05       Impact factor: 22.113

Review 6.  Structural basis of integrin regulation and signaling.

Authors:  Bing-Hao Luo; Christopher V Carman; Timothy A Springer
Journal:  Annu Rev Immunol       Date:  2007       Impact factor: 28.527

7.  Ligand density dramatically affects integrin alpha IIb beta 3-mediated platelet signaling and spreading.

Authors:  Markéta Jirousková; Jyoti K Jaiswal; Barry S Coller
Journal:  Blood       Date:  2007-03-01       Impact factor: 22.113

8.  Tests of the extension and deadbolt models of integrin activation.

Authors:  Jieqing Zhu; Brian Boylan; Bing-Hao Luo; Peter J Newman; Timothy A Springer
Journal:  J Biol Chem       Date:  2007-02-13       Impact factor: 5.157

9.  TNFα pathway blockade ameliorates toxic effects of FSGS plasma on podocyte cytoskeleton and β3 integrin activation.

Authors:  Martin Bitzan; Sima Babayeva; Anil Vasudevan; Paul Goodyer; Elena Torban
Journal:  Pediatr Nephrol       Date:  2012-04-27       Impact factor: 3.714

10.  Fine specificity of drug-dependent antibodies reactive with a restricted domain of platelet GPIIIA.

Authors:  Julie A Peterson; Tamara N Nelson; Adam J Kanack; Richard H Aster
Journal:  Blood       Date:  2007-10-24       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.